ASRS 2019

    In this interview from ASRS 2019, Dr. John Thompson reports on the incidence of silicone oil microdroplets following multiple injections of bevacizumab, ranibizumab or aflibercept. His analysis, which follows a 2017 study led by Dr. Rahul Khurana, included eyes that had received either of the 3 anti-VEGF agents and found oil droplets in 78% of bevacizumab-injected eyes, 48% of aflibercept eyes and 14% of ranibizumab eyes. Bevacizumab-associated oil bubbles tended to be more prominent. By contrast, he did not observe any silicone oil in a small group of eyes that were injected with prefilled, silicone-free ranibizumab syringes. He suggests that physicians should use silicone-free syringes for delivering bevacizumab.

    Relevant Financial Disclosures: Dr. Thompson is a consultant for and receives grant support from Genentech.